menu
    • menu
    [{"orgOrder":0,"company":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Aumolertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences \/ Hansoh Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences \/ Hansoh Pharma"},{"orgOrder":0,"company":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Aumolertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences \/ Hansoh Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences \/ Hansoh Pharma"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"EQRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Aumolertinib Mesylate","moa":"EGFR*","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ EQRx","highestDevelopmentStatusID":"15","companyTruncated":"Hansoh Pharma \/ EQRx"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aumolertinib Mesylate","moa":"||EGFR*","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansoh Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Aumolertinib Mesylate

    Menu

    Aumolertinib Mesylate

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hansoh Pharma

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aumolertinib Mesylate,Carboplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Latest Results from AENEAS Study of Hansoh Pharma's Ameile® Published in Top International Academic Journal J...

                            Details : The results of the study demonstrate the superior safety and efficacy profile of Ameile (aumolertinib) in the first-line treatment of EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC.

                            Product Name : Ameile

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 31, 2022

                            Lead Product(s) : Aumolertinib Mesylate,Carboplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cancer Institute and Hospital, Chinese Academy of Medical Sciences

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cancer Institute and Hospital, Chinese Academy of Medical Sciences

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aumolertinib Mesylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Hansoh Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene ...

                            Details : Almonertinib Mesylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 05, 2020

                            Lead Product(s) : Aumolertinib Mesylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Hansoh Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cancer Institute and Hospital, Chinese Academy of Medical Sciences

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cancer Institute and Hospital, Chinese Academy of Medical Sciences

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aumolertinib Mesylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Hansoh Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene...

                            Details : Almonertinib Mesylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 05, 2020

                            Lead Product(s) : Aumolertinib Mesylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Hansoh Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hansoh Pharma

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aumolertinib Mesylate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : EQRx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib

                            Details : Partnership aims to accelerate global access to almonertinib as a treatment for individuals with non-small cell lung cancer (NSCLC).

                            Product Name : Ameile

                            Product Type : Miscellaneous

                            Upfront Cash : $100.0 million

                            July 23, 2020

                            Lead Product(s) : Aumolertinib Mesylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : EQRx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth